查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576813

生殖器疱疹治疗市场：按类型、临床试验、给药途径、药物类别、最终用户、年龄组、患者性别 - 全球预测 2025-2030

Genital Herpes Treatment Market by Type (Antiviral Medications, Supplements, Topical Creams/Ointments), Clinical Trials (Phase I, Phase II, Phase III), Route Of Administration, Drug Class, End User, Age Group, Patient Gender - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

生殖器疱疹治疗市场2023年估值为20.8亿美元，预计到2024年将达到21.7亿美元，复合年增长率为4.80%，预计到2030年将达到29亿美元。

生殖器疱疹治疗市场的定义是旨在控制症状和减少单纯疱疹病毒感染疾病爆发的治疗药物。该系列包括阿昔洛韦、伐昔洛韦和泛昔洛韦等抗病毒药物，这些药物对于改善患者的生活品质至关重要。这种疾病的慢性性质及其流行性强调了对这些治疗的需求，这继续刺激了对处方药和非处方药的需求。最终用途包括医院、专科诊所和零售药局。影响市场的主要成长要素包括人们对诊断的认识和关注的提高、诊断技术的发展以及更有效的治疗方法和潜在疫苗的研发。个人化医疗和长期抑制治疗的发展商机不断扩大，技术创新之路也日渐清晰。然而，社会耻辱、患者依从性问题以及与替代疗法的竞争等限制带来了重大挑战。监管障碍和不断上升的研发成本将进一步拖累市场扩张。也就是说，利用远端医疗进行远距离诊断和治疗，并与策略伙伴关係推进抗病毒药物开发研究，可以创造重大的商业前景。最有前景的技术创新领域包括CRISPR-Cas9基因编辑和免疫疗法，它们有潜力开发根治性方法。竞争格局的特点是大型製药企业大力投资临床试验和探索性研究以获取市场占有率。基于这些见解，鼓励公司专注于加强患者教育倡议、降低成本以提高可及性，并建立策略合作伙伴关係以推动创新和市场渗透。这样做将促进这个充满活力且不断发展的行业的成长并产生可观的收益流。

主要市场统计
基准年[2023] 20.8亿美元
预测年份 [2024] 21.7亿美元
预测年份 [2030] 29亿美元
复合年增长率（%） 4.80%

市场动态：快速发展的生殖器疱疹治疗市场的关键市场洞察

供需的动态交互作用正在改变生殖器疱疹治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 早期核准新的生殖器疱疹治疗方法的法规结构的演变
    • 社群媒体和数位平台对传播生殖器疱疹治疗方案认识的影响
    • 抗病毒药物抗药性的增加需要开发新的治疗方法
    • 个人化治疗对生殖器疱疹患者的重要性日益增加
  • 市场限制因素
    • 由于病毒的复杂性，开发生殖器疱疹疫苗面临挑战
  • 市场机会
    • 利用先进的给药系统提高疗效和病人依从性
    • 将全面的性健康教育纳入生殖器疱疹治疗计划
    • 扩大基因组研究，为生殖器疱疹患者开发个人化治疗方法
  • 市场挑战
    • 与生殖器疱疹相关的耻辱和耻辱导致诊断和治疗的延误

波特五力：开拓生殖器疱疹治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生殖器疱疹治疗市场的外部影响

外部宏观环境因素在塑造生殖器疱疹治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生殖器疱疹治疗市场的竞争状况

生殖器疱疹治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生殖器疱疹治疗市场供应商的绩效评估

FPNV定位矩阵是评估生殖器疱疹治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了生殖器疱疹治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，生殖器疱疹治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 快速核准生殖器疱疹新疗法的法规结构的演变
      • 社群媒体和数位平台对传播生殖器疱疹治疗方案认识的影响
      • 抗病毒药物抗药性的蔓延需要开发新的治疗方法
      • 个人化医疗对于生殖器疱疹患者的客製化治疗越来越重要
    • 抑制因素
      • 由于病毒的复杂性，生殖器疱疹疫苗开发面临挑战
    • 机会
      • 利用先进的给药系统提高生殖器疱疹治疗效果和患者依从性
      • 将全面的性教育纳入您的生殖器疱疹治疗计划
      • 扩大基因组研究，为生殖器疱疹患者开发个人化治疗方案
    • 任务
      • 与生殖器疱疹相关的耻辱和耻辱导致诊断和治疗的延误
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 生殖器疱疹治疗市场：依类型

  • 抗病毒药物
    • 阿昔洛韦
    • 泛昔洛韦
    • 伐昔洛韦
  • 补充品
  • 外用乳霜/软膏

第七章临床试验的生殖器疱疹治疗市场

  • 第一阶段
  • 第二阶段
  • 第三阶段

第八章 生殖器疱疹治疗市场：依给药途径

  • 可注射的
  • 口服
  • 话题

第九章按药物类别分類的生殖器疱疹治疗市场

  • 抗病毒药
  • 免疫调节剂

第 10 章 生殖器疱疹治疗市场：依最终使用者分类

  • 诊所
  • 家庭护理设置
  • 医院
  • 药局

第十一章生殖器疱疹治疗市场：依年龄组

  • 成人
  • 老年医学
  • 小儿科

第十二章生殖器疱疹治疗市场患者性别

  • 女士
  • 男人

第十三章北美和南美洲生殖器疱疹治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太地区生殖器疱疹治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章 欧洲、中东和非洲生殖器疱疹治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0410

The Genital Herpes Treatment Market was valued at USD 2.08 billion in 2023, expected to reach USD 2.17 billion in 2024, and is projected to grow at a CAGR of 4.80%, to USD 2.90 billion by 2030.

The market for genital herpes treatment is defined by therapies aimed at managing symptoms and reducing outbreaks of herpes simplex virus infections. This scope encompasses antiviral medications, such as acyclovir, valacyclovir, and famciclovir, which are essential for improving patient quality of life. The necessity of these treatments is underscored by the chronic nature of the condition and its prevalence, which continues to stimulate demand for both prescription medications and over-the-counter options. Application primarily targets disease management and transmission reduction, while end-use includes hospitals, specialty clinics, and retail pharmacies. Key growth factors influencing the market involve increased awareness and diagnosis, technological advancements in diagnostics, and a growing focus on research and development for more effective therapies and potential vaccines. Opportunities are surfacing in personalized medicine and the development of long-term suppressive therapies, presenting avenues for innovation. However, limitations such as social stigma, patient adherence issues, and competition from alternative therapies pose significant challenges. Regulatory hurdles and high costs of R&D further strain market expansion. Nonetheless, leveraging telehealth for remote diagnosis and treatment, along with strategic partnerships for advancing research in antiviral drug development, can create substantial business prospects. The most promising areas for innovation involve exploring CRISPR-Cas9 gene editing and immunotherapy as potential forays to develop curative treatments. The genital herpes treatment market is characterized by a competitive landscape with major pharmaceutical companies investing heavily in clinical trials and exploratory research to capture market share. Building on these insights, businesses are advised to focus on enhancing patient education initiatives, reducing costs to improve accessibility, and developing strategic alliances to boost innovation and market penetration. This will foster growth and generate substantial revenue streams within this dynamic and continuously evolving sector.

KEY MARKET STATISTICS
Base Year [2023] USD 2.08 billion
Estimated Year [2024] USD 2.17 billion
Forecast Year [2030] USD 2.90 billion
CAGR (%) 4.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genital Herpes Treatment Market

The Genital Herpes Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Evolving regulatory frameworks aimed at fast-tracking approvals of new genital herpes treatments
    • The influence of social media and digital platforms in spreading awareness about genital herpes treatment options
    • Rising prevalence of antiviral resistance necessitating the development of new treatment modalities
    • Growing importance of personalized medicine in tailoring treatments for genital herpes patients
  • Market Restraints
    • Challenges in developing a vaccine for genital herpes due to the complex nature of the virus
  • Market Opportunities
    • Leveraging advanced drug delivery systems to improve genital herpes treatment efficacy and patient adherence
    • Integrating comprehensive sexual health education into treatment plans for genital herpes
    • Expanding genomic research to develop personalized treatment options for genital herpes patients
  • Market Challenges
    • Stigma and embarrassment associated with genital herpes leading to delayed diagnosis or treatment

Porter's Five Forces: A Strategic Tool for Navigating the Genital Herpes Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genital Herpes Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genital Herpes Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genital Herpes Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genital Herpes Treatment Market

A detailed market share analysis in the Genital Herpes Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genital Herpes Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genital Herpes Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genital Herpes Treatment Market

A strategic analysis of the Genital Herpes Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genital Herpes Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Mylan, Novartis, Pfizer, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Vertex Pharmaceuticals, and ViiV Healthcare.

Market Segmentation & Coverage

This research report categorizes the Genital Herpes Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antiviral Medications, Supplements, and Topical Creams/Ointments. The Antiviral Medications is further studied across Acyclovir, Famciclovir, and Valacyclovir.
  • Based on Clinical Trials, market is studied across Phase I, Phase II, and Phase III.
  • Based on Route Of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Drug Class, market is studied across Antiviral and Immune Modulators.
  • Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Pharmacies.
  • Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.
  • Based on Patient Gender, market is studied across Female and Male.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Evolving regulatory frameworks aimed at fast-tracking approvals of new genital herpes treatments
      • 5.1.1.2. The influence of social media and digital platforms in spreading awareness about genital herpes treatment options
      • 5.1.1.3. Rising prevalence of antiviral resistance necessitating the development of new treatment modalities
      • 5.1.1.4. Growing importance of personalized medicine in tailoring treatments for genital herpes patients
    • 5.1.2. Restraints
      • 5.1.2.1. Challenges in developing a vaccine for genital herpes due to the complex nature of the virus
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging advanced drug delivery systems to improve genital herpes treatment efficacy and patient adherence
      • 5.1.3.2. Integrating comprehensive sexual health education into treatment plans for genital herpes
      • 5.1.3.3. Expanding genomic research to develop personalized treatment options for genital herpes patients
    • 5.1.4. Challenges
      • 5.1.4.1. Stigma and embarrassment associated with genital herpes leading to delayed diagnosis or treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genital Herpes Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Antiviral Medications
    • 6.2.1. Acyclovir
    • 6.2.2. Famciclovir
    • 6.2.3. Valacyclovir
  • 6.3. Supplements
  • 6.4. Topical Creams/Ointments

7. Genital Herpes Treatment Market, by Clinical Trials

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III

8. Genital Herpes Treatment Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Genital Herpes Treatment Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Antiviral
  • 9.3. Immune Modulators

10. Genital Herpes Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare Settings
  • 10.4. Hospitals
  • 10.5. Pharmacies

11. Genital Herpes Treatment Market, by Age Group

  • 11.1. Introduction
  • 11.2. Adults
  • 11.3. Geriatrics
  • 11.4. Pediatrics

12. Genital Herpes Treatment Market, by Patient Gender

  • 12.1. Introduction
  • 12.2. Female
  • 12.3. Male

13. Americas Genital Herpes Treatment Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Genital Herpes Treatment Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Genital Herpes Treatment Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Biogen
  • 6. Bristol-Myers Squibb
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline
  • 11. Johnson & Johnson
  • 12. Merck & Co.
  • 13. Mylan
  • 14. Novartis
  • 15. Pfizer
  • 16. Sanofi
  • 17. Takeda Pharmaceutical
  • 18. Teva Pharmaceutical Industries
  • 19. Vertex Pharmaceuticals
  • 20. ViiV Healthcare

LIST OF FIGURES

  • FIGURE 1. GENITAL HERPES TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GENITAL HERPES TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. GENITAL HERPES TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. GENITAL HERPES TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENITAL HERPES TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENITAL HERPES TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FAMCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY VALACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY IMMUNE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENITAL HERPES TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENITAL HERPES TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GENITAL HERPES TREATMENT MARKET SIZE, BY PATIENT GENDER, 2018-2030 (USD MILLION)
  • TABLE 322. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN GENITAL HERPES TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN GENITAL HERPES TREATMENT MARKET SI